Purpose Panitumumab monotherapy is approved for chemotherapy-refractory wild-type metastatic colorectal tumor
Purpose Panitumumab monotherapy is approved for chemotherapy-refractory wild-type metastatic colorectal tumor (mCRC). [LS] adjusted means [95% CI]; 5.62 [2.38 8.86 and the EQ-5D Index (difference in LS adjusted means [95% CI]; 0.22 [0.12 0.32 favoring panitumumab over BSC in patients with wild-type mCRC. By pattern-mixture analysis the advantage of panitumumab over BSC was more pronounced … [Read more…]